Literature DB >> 16141533

Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis.

Takayuki Seki1, Mong-Heng Wang, Noriyuki Miyata, Michal Laniado-Schwartzman.   

Abstract

We examined the effect of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine) (HET0016), an inhibitor of 20-hydroxy-5,8,11,14-eicosatetraenoic acid (20-HETE) synthesis on the omega-hydroxylation and epoxidation of arachidonic acid (AA) catalyzed by recombinant cytochrome P450 4A1 (CYP4A1), CYP4A2 and CYP4A3, and characterized the enzyme inhibitory profile of HET0016. The IC50 values of HET0016 for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis averaged 17.7 nM, 12.1 nM and 20.6 nM, respectively. The IC50 value for production of 11,12-epoxy-5,8,14-eicosatrienoic acid (11,12-EET) by CYP4A2 and 4A3 averaged 12.7 nM and 22.0 nM, respectively. The IC50 value for CYP2C11 activity was 611 nM which was much greater than that for CYP4As. The initial velocity study showed the Ki value of HET0016 for CYP4A1 was 19.5 nM and a plot of Vmax versus amount of recombinant CYP4A1 added shows HET0016 is an irreversible non-competitive inhibitor. These results indicate that HET0016 is a selective, non-competitive and irreversible inhibitor of CYP4A.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141533     DOI: 10.1248/bpb.28.1651

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  20 in total

1.  Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016.

Authors:  O T Parkinson; E J Kelly; E Bezabih; D Whittington; A E Rettie
Journal:  J Vet Pharmacol Ther       Date:  2011-09-15       Impact factor: 1.786

Review 2.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

3.  Protective effect of 20-HETE inhibition in a model of oxygen-glucose deprivation in hippocampal slice cultures.

Authors:  Marija Renic; Suresh N Kumar; Debebe Gebremedhin; Matthew A Florence; Nashaat Z Gerges; John R Falck; David R Harder; Richard J Roman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-13       Impact factor: 4.733

4.  Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.

Authors:  Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-01       Impact factor: 3.333

5.  Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.

Authors:  Kartik Angara; Mohammad H Rashid; Adarsh Shankar; Roxan Ara; Asm Iskander; Thaiz F Borin; Meenu Jain; Bhagelu R Achyut; Ali S Arbab
Journal:  Histol Histopathol       Date:  2016-12-19       Impact factor: 2.303

Review 6.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

7.  Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.

Authors:  Wei Yu; Hongyan Chai; Ying Li; Haixia Zhao; Xianfei Xie; Hao Zheng; Chenlong Wang; Xue Wang; Guifang Yang; Xiaojun Cai; John R Falck; Jing Yang
Journal:  Toxicol Appl Pharmacol       Date:  2012-07-25       Impact factor: 4.219

8.  Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles.

Authors:  Ying Ge; Sydney R Murphy; Yan Lu; John Falck; Ruisheng Liu; Richard J Roman
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-03-14       Impact factor: 3.072

9.  Intravenous formulation of N-hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for inhibition of rat brain 20-hydroxyeicosatetraenoic acid formation.

Authors:  Ying Mu; Megan M Klamerus; Tricia M Miller; Lisa C Rohan; Steven H Graham; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

10.  20-HETE-producing enzymes are up-regulated in human cancers.

Authors:  Anna Alexanian; Bradley Miller; Richard J Roman; Andrey Sorokin
Journal:  Cancer Genomics Proteomics       Date:  2012 Jul-Aug       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.